Work

Advancing paediatric allergy care: key findings from the largest trial of house dust mite sublingual immunotherapy-tablets in children

Year: 2024

Type: article

Abstract: Allergic rhinitis and rhinoconjunctivitis (AR/C) caused by house dust mites (HDM) significantly burden children's daily lives.1 Despite allergen reduction and pharmacotherapy, many children experience substantial symptoms and impaired quality of life,2 highlighting the need for disease-modifying treatments like allergen immunotherapy (AIT). In this issue, Schuster et al.3 present compelling results from the largest double-blind, placebo-controlled trial of SQ HDM sublingual immunotherapy (SLIT)-tablets or placebo for one year in children aged 5–11 years (n = 1460) with physician-diagnosed HDM AR/C from 95 sites across Europe and North America. The primary outcome was the Total Combined Rhinitis Score during the final 8 weeks of treatment, where a 22% reduction was demonstrated with the HDM SLIT-tablet compared to placebo (absolute difference, 1.0, 95% CI: 0.5–1.4; p < 0.0001), which exceeds the minimal clinically important difference of 15%

Source: The Lancet Regional Health - Europe

DOI: 10.1016/j.lanepe.2024.101167

Authors: Ann-Marie Malby Schoos, Bo Chawes

Institutions: University of Copenhagen, Gentofte Hospital, Slagelse Hospital, Copenhagen Prospective Studies on Asthma in Childhood, Herlev Hospital

Language: English

Topic: Allergic Rhinitis and Sensitization

Subfield: Immunology and Allergy

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

Estimated APC paid: $4,000